ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Axillary management in patients with cN + breast cancer undergoing neoadjuvant chemotherapy: pattern of practice in Italy.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the current practices concerning the axillary management of clinically node-positive (cN +) breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC), among radiation oncologists (ROs) practicing in Italy.
methodsAn online 24-question survey was distributed via SurveyMonkey to ROs between December 2024 and February 2025. This survey was developed through a multistep process by the Clinical Oncology Breast Cancer Group (COBCG) and AIRO Breast Cancer study groups' experts, focusing on axillary lymph node dissection (ALND) omission after pathological complete response (pCR) and its implications for regional nodal irradiation (RNI). The survey followed the CHERRIES statement and ESTRO guidelines and was revised and approved by the scientific committee of AIRO (Nr. 21/2024).
results119/195 (61%) Italian Radiotherapy Centers, mostly public hospitals, completed the survey. Regarding cN + disease at diagnosis and node-negative disease (ypN0) on sentinel lymph node biopsy (SLNB) after NAC, ALND was omitted a) always, b) when three sentinel nodes were removed, c) never, and d) only in selected cases, in 26.05%, 45.38%, 2.52% and 26.05%, respectively. Most respondents (80%) said ALND omission was a multidisciplinary decision. According to 48.60%, ALND was omitted in cN1 disease. RNI indications varied in patients not undergoing ALND. Among 70 respondents defining RNI target volumes in cN2-3 patients without ALND, 62.86% treated all nodal levels (I-IV). Key factors influencing RNI included pre-NAC lymph node burden (56.72%), extracapsular nodal extension (43.94%), and tumor size (40.63%).
conclusionsAxillary management of BC patients undergoing NAC in Italy is moving toward treatment de-escalation, with relevant variability, supporting the need for multidisciplinary harmonization.
Indexed as
Identifiers
42234294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.